Ann: Phosphagenics Newsletter - August 2018, page-28

As has been previously higlighted from the newsletter:
"I would also like shareholders to again note that the that the ongoing existence of the Licensing Agreement between our company and Mylan Laboratories Limited will not be impacted by the arbitration outcome and will continue to be in force. Our company therefore continues to work within, and actively protect our rights under, the Licensing Agreement'".
My understanding of the Mylan arbitration event is that the arbitrator refers to any matters presented  to the arbitrator up to and including final submissions  and that any matters arising after that time cannot be submitted and therefore should have no impact on the arbitration end result.
If the above newsletter  statement is correct[and I hope it it is] and  the POH total daptomycin damages claim of US $300K includes forward looking  loss estimates, I am finding it difficult to understand  that the above statement does represent a form of double dipping.If it is not double dipping then a positive outcome here could exceed all of my current expectations which is probably why RM has raised the matter in the first place.
Kens